Faculty

Institution

Unit

Venue

Ekere Essien

Professor of Pharmaceutical Health Outcomes and Policy

University of Houston

Affiliations

College of Pharmacy

Pharmaceutical Health Outcomes and Policy

Ekere Essien is currently serving as a College Of Pharmacy Professor of Pharmaceutical Health Outcomes and Policy at University of Houston.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Ekere Essien

University of Houston

Professor of Pharmaceutical Health Outcomes and Policy

You can click a keyword to filter the displayed items

public health health policy hiv global health health care epidemiology tobacco control respiratory medicine adolescent health mental health health services research virology pharmacotherapy tobacco use united states behavioral health international health infection control racial discrimination addiction medicine disease prevention health care disparities health disparities clinical pharmacy health care management clinical pharmacology clinical implementation disease risk assessment sexual health military psychology substance use social epidemiology chronic disease management cigarette smoking medicare advantage plan motivational interviewing intervention harm reduction correctional practice patient management adolescent psychology ethnic studies symptom management infectious disease modelling emerging risk disease transmission cohort studies medication adherence obstetrics and gynaecology health planning risk communication emerging infectious diseases child health patient support adolescence diabetes management waterpipe smoking sub-saharan africa pharmacological research women's studies addictive behaviors sexology clinical practice military sociology later adulthood health prevention cross-sectional studies hiv transmission military personnel older adults research studies evidence-based practice street outreach samples health workers niger delta region comorbid hypertension cross river state treatment and prevention health equity hiv risk reduction social determinants of health preventive healthcare preventive medicine healthcare provision

Notable Scholarly Works

Notable Federal Grants

Collaborators

Comparative Effectiveness of High-Efficacy and Moderate Efficacy Disease-Modifying Agents in Reducing the Annualized Relapse Rates Among Multiple Sclerosis Patients in the United States. Preventive Medicine (2024)

Jieni LiGeorge J HuttonTyler J VariscoYing LinEkere J EssienRajender R Aparasu

public healthmultiple sclerosisrelapse ratesclinical effectivenessmultiple sclerosis patientsrelapse preventionunited statespreventive medicinedisease prevention

Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas. American Journal of Clinical Oncology (2024)

Olajumoke A. OlatejuOsaro MgbereJ. Douglas ThorntonZhen ZengEkere J. Essien

dermatologymedicinemelanomacancer carehealth disparitiesdisparitiescancer managementmetastatic melanomasurvival outcomeshealth care disparitiesclinical trialsregional studiesoncologyclinical researchclinical epidemiologymedicinal researchskin cancerhealth sciences

Eph235 Impact of Real-Time Containment Measures on Covid-19 Pandemic Outcomes in African Countries. Value in Health (2024)

O MgbereT Temedie-AsogwaO AdepojuW LiawC DarkohEJ Essien

public healthoutcomes researchcovid-19 pandemichealth economicsglobal healthinfectious diseasesafrican countriesdisease preventionreal-time containment measuresdisease control

Factors Associated With the Initiation of High-Efficacy Disease-Modifying Agents Over Moderate-Efficacy Disease-Modifying Agents in Multiple Sclerosis. Multiple Sclerosis and Related Disorders (2024)

Jieni LiGeorge J HuttonTyler J VariscoYing LinEkere J EssienRajender R Aparasu

neurologyneurological disordersmultiple sclerosisneuropharmacologyhigh-efficacy disease-modifying agentstherapeutic efficacymoderate-efficacy disease-modifying agents

First-Line Treatment Patterns and Associated Survival Among Older Patients With Advanced Cancer. Research in Social and Administrative Pharmacy (2024)

O.A. OlatejuO.O. MgbereJ.D. ThorntonE.J. Essien

medicinepharmacologyfirst-line treatment patternsepidemiologysurvival analysisclinical pharmacypharmacotherapygeriatric medicineadvanced canceroncologyclinical researchrespiratory medicinecancer treatmentgeriatricsclinical gerontologyolder patients

Group-Based Trajectory Modeling to Identify Adherence Patterns for Direct Oral Anticoagulants in Medicare Beneficiaries With Atrial Fibrillation. Research Square (Research Square) (2024)

Anjana MohanHua ChenAshish A. DeshmukhMatthew WanatEkere James EssienRutugandha ParanjpeBilqees FatimaSusan Abughosh

health insurancepharmacoepidemiologyhealth services researchcardiovascular interventionsdirect oral anticoagulantsmedicare beneficiariesadherence patternsclinical pharmacologypublic healthgroup-based trajectoryresearch designpharmaceutical careatrial fibrillationdrug deliveryhealth policycardiologyresearch policypharmacologyhealth carepharmacotherapyresearch-practice partnershipsrespiratory medicineintensive care

Group-Based Trajectory Modeling to Identify Adherence Patterns for Direct Oral Anticoagulants in Medicare Beneficiaries With Atrial Fibrillation: A Real-World Study on Medication Adherence. International Journal of Clinical Pharmacy (2024)

Anjana MohanHua ChenAshish A. DeshmukhMatthew WanatEkere James EssienRutugandha ParanjpeBilqees FatimaSusan Abughosh

pharmacoepidemiologyhealth services researchdirect oral anticoagulantsapplied pharmacologyfamily medicinemedicare beneficiariesclinical epidemiologyadherence patternspublic healthpreventive healthcaregroup-based trajectorypharmaceutical careatrial fibrillationcardiologyanticoagulantsaddiction medicinepatient monitoringpreventive medicinepharmacologypharmacotherapyclinical trialsdiabetic medicinetreatment options

Impact of Adherence on the Cost-Effectiveness of Apixaban and Rivaroxaban in Stroke Prevention Among Patients With Atrial Fibrillation in the United States. Expert Review of Pharmacoeconomics & Outcomes Research (2024)

Anjana MohanHaluk DamgaciogluAshish A. DeshmukhHua ChenMatthew WanatEkere James EssienRutugandha ParanjpeBilqees FatimaSusan Abughosh

pharmacoepidemiologyapplied pharmacologyunited statesantihypertensive therapyclinical pharmacologypublic healthmedicineoutcomes researchstroke preventionthrombosisstroke rehabilitationatrial fibrillationpharmacoeconomicsclinical effectivenessstrokepharmacologypharmacotherapyclinical trialshealth economicsintensive carecardiovascular disease

Infection Risk Associated With High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clinical Pharmacology & Therapeutics (2024)

Jieni LiGeorge J. HuttonTyler J. VariscoYing LinEkere J. EssienRajender R. Aparasu

public healthdisease transmissionmultiple sclerosisinfection riskclinical researchhigh-efficacy disease-modifying agentsinfectious diseasesclinical pharmacology

Protocol for the Development of a Consensus Practice Guideline to Address Clinical and Regulatory Barriers to Buprenorphine Dispensing in Community Pharmacy. Archives of Public Health (2024)

Tyler J. VariscoHannah FishJoshua BolinDavid DadiomovLucas G. HillEkere J. EssienMatthew A. WanatDiane GinsburgJeanne WaggenerSahar YazdanfardJuhyeon SongWhanhui ChiDouglas Thornton

public healthpharmacologyconsensus practice guidelinecommunity pharmacyregulatory barriersdrug deliveryhealth policy

1
2
3
4
5
20
10 / page

Ekere Essien

Professor of Pharmaceutical Health Outcomes and Policy

University of Houston

Affiliations

College of Pharmacy

Pharmaceutical Health Outcomes and Policy

Ekere Essien is currently serving as a College Of Pharmacy Professor of Pharmaceutical Health Outcomes and Policy at University of Houston.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Ekere Essien

University of Houston

Professor of Pharmaceutical Health Outcomes and Policy

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Jieni LiGeorge J HuttonTyler J VariscoYing LinEkere J EssienRajender R Aparasu

public healthmultiple sclerosisrelapse ratesclinical effectivenessmultiple sclerosis patientsrelapse preventionunited statespreventive medicinedisease prevention

Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas. American Journal of Clinical Oncology (2024)

Olajumoke A. OlatejuOsaro MgbereJ. Douglas ThorntonZhen ZengEkere J. Essien

Eph235 Impact of Real-Time Containment Measures on Covid-19 Pandemic Outcomes in African Countries. Value in Health (2024)

O MgbereT Temedie-AsogwaO AdepojuW LiawC DarkohEJ Essien

public healthoutcomes researchcovid-19 pandemichealth economicsglobal healthinfectious diseasesafrican countriesdisease preventionreal-time containment measuresdisease control

Jieni LiGeorge J HuttonTyler J VariscoYing LinEkere J EssienRajender R Aparasu

neurologyneurological disordersmultiple sclerosisneuropharmacologyhigh-efficacy disease-modifying agentstherapeutic efficacymoderate-efficacy disease-modifying agents

First-Line Treatment Patterns and Associated Survival Among Older Patients With Advanced Cancer. Research in Social and Administrative Pharmacy (2024)

O.A. OlatejuO.O. MgbereJ.D. ThorntonE.J. Essien

Group-Based Trajectory Modeling to Identify Adherence Patterns for Direct Oral Anticoagulants in Medicare Beneficiaries With Atrial Fibrillation. Research Square (Research Square) (2024)

Anjana MohanHua ChenAshish A. DeshmukhMatthew WanatEkere James EssienRutugandha ParanjpeBilqees FatimaSusan Abughosh

Anjana MohanHaluk DamgaciogluAshish A. DeshmukhHua ChenMatthew WanatEkere James EssienRutugandha ParanjpeBilqees FatimaSusan Abughosh

Infection Risk Associated With High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clinical Pharmacology & Therapeutics (2024)

Jieni LiGeorge J. HuttonTyler J. VariscoYing LinEkere J. EssienRajender R. Aparasu

public healthdisease transmissionmultiple sclerosisinfection riskclinical researchhigh-efficacy disease-modifying agentsinfectious diseasesclinical pharmacology

Protocol for the Development of a Consensus Practice Guideline to Address Clinical and Regulatory Barriers to Buprenorphine Dispensing in Community Pharmacy. Archives of Public Health (2024)

Tyler J. VariscoHannah FishJoshua BolinDavid DadiomovLucas G. HillEkere J. EssienMatthew A. WanatDiane GinsburgJeanne WaggenerSahar YazdanfardJuhyeon SongWhanhui ChiDouglas Thornton

public healthpharmacologyconsensus practice guidelinecommunity pharmacyregulatory barriersdrug deliveryhealth policy

1
2
3
4
5
20
10 / page

Similar Faculty Members

Susan Abughosh

Institution

University of Houston

health policy

harm reduction

Robert L Cook

Institution

University of Florida

public health

hiv

Purnima Madhivanan

Institution

University of Arizona

communicable disease

global health

Daniel J Feaster

Institution

University of Miami

hiv

global health

Trace Kershaw

Institution

Yale University

public health

behavioral sciences

Brandon David Lewis Marshall

Institution

Brown University

harm reduction

preventive medicine

William Miller

Institution

University of North Carolina at Chapel Hill

preventive medicine

population health

Electra Paskett

Institution

Ohio State University

cancer disparities

health policy

Adaora Adimora

Institution

University of North Carolina at Chapel Hill

infectious diseases (medical specialty)

commercial sex

Sten Vermund

Institution

Yale University

public health

hiv

Similar Faculty Members

Susan Abughosh

Institution

University of Houston

health policy

harm reduction

Robert L Cook

Institution

University of Florida

public health

hiv

Purnima Madhivanan

Institution

University of Arizona

communicable disease

global health

Daniel J Feaster

Institution

University of Miami

hiv

global health

Trace Kershaw

Institution

Yale University

public health

behavioral sciences

Brandon David Lewis Marshall

Institution

Brown University

harm reduction

preventive medicine

William Miller

Institution

University of North Carolina at Chapel Hill

preventive medicine

population health

Electra Paskett

Institution

Ohio State University

cancer disparities

health policy

Adaora Adimora

Institution

University of North Carolina at Chapel Hill

infectious diseases (medical specialty)

commercial sex

Sten Vermund

Institution

Yale University

public health

hiv